Free Trial

Krystal Biotech (KRYS) Competitors

Krystal Biotech logo
$148.17 -1.57 (-1.05%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$150.57 +2.40 (+1.62%)
As of 07/11/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KRYS vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMC

Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.

Krystal Biotech vs. Its Competitors

Krystal Biotech (NASDAQ:KRYS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, Krystal Biotech had 15 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 16 mentions for Krystal Biotech and 1 mentions for Intra-Cellular Therapies. Krystal Biotech's average media sentiment score of 0.39 beat Intra-Cellular Therapies' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intra-Cellular Therapies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Krystal Biotech presently has a consensus price target of $213.75, indicating a potential upside of 44.26%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Intra-Cellular Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00
Intra-Cellular Therapies
0 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Krystal Biotech has a net margin of 37.17% compared to Intra-Cellular Therapies' net margin of -14.07%. Krystal Biotech's return on equity of 14.64% beat Intra-Cellular Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech37.17% 14.64% 13.28%
Intra-Cellular Therapies -14.07%-9.93%-8.38%

Krystal Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Krystal Biotech has higher earnings, but lower revenue than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$333.45M12.84$89.16M$4.1635.62
Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Krystal Biotech beats Intra-Cellular Therapies on 13 of the 17 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KRYS vs. The Competition

MetricKrystal BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.28B$2.94B$5.56B$9.11B
Dividend YieldN/A2.42%5.07%4.01%
P/E Ratio35.6220.7128.2120.26
Price / Sales12.84292.31432.3899.78
Price / Cash31.9542.1137.1257.67
Price / Book4.507.638.045.49
Net Income$89.16M-$55.05M$3.19B$250.45M
7 Day Performance3.61%8.43%3.63%4.79%
1 Month Performance5.59%5.42%4.06%7.68%
1 Year Performance-27.06%2.03%30.02%16.44%

Krystal Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRYS
Krystal Biotech
4.6729 of 5 stars
$148.17
-1.0%
$213.75
+44.3%
-25.3%$4.28B$333.45M35.62210Trending News
Analyst Forecast
Insider Trade
Analyst Revision
ITCI
Intra-Cellular Therapies
0.6588 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
4.0949 of 5 stars
$20.52
+1.1%
$37.60
+83.2%
-18.4%$13.02B$3.12B11.662,682Positive News
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.768 of 5 stars
$15.08
flat
$16.95
+12.4%
-7.9%$12.59B$325.54B22.8527,811
MRNA
Moderna
4.3051 of 5 stars
$29.90
-1.9%
$46.61
+55.9%
-72.6%$11.79B$3.24B-3.425,800Trending News
RGC
Regencell Bioscience
0.3692 of 5 stars
$18.43
-19.8%
N/AN/A$11.37BN/A0.0010Gap Up
High Trading Volume
VTRS
Viatris
2.903 of 5 stars
$9.20
-1.3%
$10.40
+13.0%
-18.5%$10.94B$14.74B-2.9032,000
QGEN
QIAGEN
4.0453 of 5 stars
$47.49
-1.8%
$49.40
+4.0%
+20.4%$10.75B$1.98B119.075,765
ASND
Ascendis Pharma A/S
3.6012 of 5 stars
$175.98
+1.0%
$220.67
+25.4%
+28.9%$10.65B$393.54M-28.021,017News Coverage
Analyst Forecast
BBIO
BridgeBio Pharma
4.6053 of 5 stars
$43.50
-1.1%
$58.85
+35.3%
+72.8%$8.35B$221.90M-12.32400Analyst Upgrade
BPMC
Blueprint Medicines
1.2242 of 5 stars
$128.40
+0.0%
$128.06
-0.3%
+9.8%$8.29B$508.82M-51.98640Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:KRYS) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners